chemotherapy - A type of cancer that arises from a particular
central nervous system original neuroectodermal tumor. A type of cancer that arises from a particular type of cell within the brain or spinal cord. Also called central nervous system primitive neuroectodermal tumor. CNS prophylaxis (...pro-fih-LAK-sis) Central nervous system prophylaxis. chemotherapy or radiotherapy given to the central nervous system (CNS) as a preventive treatment. It is given to kill cancer cells that may be in the brain and spinal cord, even though no cancer has been detected there. Also called central nervous system prophylaxis, central nervous system sanctuary therapy, and CNS sanctuary therapy. CNS sanctuary therapy (...SANK-choo-wayr-ee THAYR-uh-pee) Central nervous system sanctuary therapy. chemotherapy or radiotherapy given too the central nervous system (CNS) as a preventive treatment. It is given to kill cancer cells that may be in the brain and spinal cord, even though no cancer has been detected there. Also called central nervous system sanctuary therapy, central nervous system prophylaxis, and CNS prophylaxis.
chemo for patients with high risk stage I nonseminoma. Their thought is that if they can't see the spread of cancer on CT scan, but the pathology report indicates that it is likely to have spread, then they can save the patient from surgery or excessive chemo by giving them just two cycles of BEP chemo right away. Unfortunately, neither I nor most of the experts I have talked with agree with this thinking. First of all, the success rate of the standard chemotherapy and the surgical procedures is like that high (~98%) that it would take a very large sample of people to ever prove that the 2 cycle regimen is equivalent to the existing protocol. It would take many years to get enough people to run the study, and even then, you would have to watch for many years to ensure that no one is suffering from recurrences years later. Secondly, the argument for using two cycles of chemo is based on the fact that only microscopic clumps of cancer have spread so far. This is a very poor assumption. Unfortunately, the CT scan that we often rely on is only accurate 80% of the time. In other words, 20% of the time it may be falsely negative - 20% of the time it says there are no enlarged nodes when, in fact, there are enlarged nodes. I know of one person who was told that he was stage I, and was thinking about the two cycle approach. He decided to choose surgery instead. When they opened him up, they found LOTS of cancer. If he had been treated with just two cycles of chemo, it would not have been enough to cure him, but it probably would have been enough to make the cancer resistant to cisplatin based chemo.
cns pnet . A type of cancer that arises from a particular type of cell within the brain or spinal cord. Also called CNS PNET. central nervous system prophylaxis (SEN-trul NER-vus SIS-tem pro-fih-LAK-sis) CNS prophylaxis. chemotherapy or radiotherapy given to the central nervous system (CNS) as a preventive treatment. It is given to kill cancer cells that may be in the brain and spinal cord, even though no cancer has been detected there. Also called CNS prophylaxis, central nervous system sanctuary therapy, and CNS sanctuary therapy. central nervous system sanctuary therapy (SEN-trul NER-vus SIS-tem SANK-choo-WAYR-ee THAYR-uh-pee) CNS sanctuary therapy. chemotherapy or radiotherapy given too the central nervous system (CNS) as a preventive treatment. It is given to kill cancer cells that may be in the brain and spinal cord, even though no cancer has been detected there. Also called CNS sanctuary therapy, central nervous system prophylaxis, and CNS prophylaxis.
doxorubicin ) is being evaluated for use in myeloma. This new formulation provides for a slow release of doxorubicin, thus exposing myeloma cells to the drug for a longer period of time. It may also result in an improved toxicity profile due to the potential for use of lower doses of doxorubicin, preferential accumulation of the drug at the tumor site and less exposure to the rest of the body, a shorter infusion time, and less damage to heart muscle, a common complication seen when doxorubicin is given at high doses or over a period of time. The combination of Doxil, vincristine, and reduced dose dexamethasone (DVd) has recently been shown to be effective as induction therapy. Get more information about Doxil The table below conventional lists chemotherapy and other drug governments that are commonly used or under investigation for the treatment of multiple myeloma. Many of these regimens produce similar results, but they differ in various ways, including how fast they work and how well they are tolerated. In addition, these drugs vary in their suitability for use as induction therapy. Examples of Conventional Treatment Regimens Suitable for use as induction therapy?
doxorubicin ) is being evaluated for use in myeloma. This new formulation provides for a slow release of doxorubicin, thus exposing myeloma cells to the drug for a longer period of time. It may also result in an improved toxicity profile due to the potential for use of lower doses of doxorubicin, preferential accumulation of the drug at the tumor site and less exposure to the rest of the body, a shorter infusion time, and less damage to heart muscle, a common complication seen when doxorubicin is given at high doses or over a period of time. The combination of Doxil, vincristine, and reduced dose dexamethasone (DVd) has recently been shown to be effective as induction therapy. Get more information about Doxil The table below conventional lists chemotherapy and other drug governments that are commonly used or under investigation for the treatment of multiple myeloma. Many of these regimens produce similar results, but they differ in various ways, including how fast they work and how well they are tolerated. In addition, these drugs vary in their suitability for use as induction therapy. Examples of Conventional Treatment Regimens Suitable for use as induction therapy?
response of dr. nichols' was achieved, „ Bleo should be given since it doesn't really effect the white count. We always give Bleo irrespective of the white blood cell count. We don't usually add neupogen at this point since it takes several days to work, and he already is starting to recover. His next cycle should be initiated as planned irrespective of the white count. Patients are almost always recovering at that point." I later asked Dr Nichols specifically, "Under what circumstances would you postpone the start of the next BEP cycle? Would your answer change if the protocol was VIP?" He says that, "The correct answer is very rarely for any circumstances related to myelosuppression. What we do is start virtually everyone on the correct day and watch their counts over the 5 days. If, and this is very uncommon, the white count doesn't start to rise we hold the last day of etoposide. Most everyone has a rising white count at that juncture. There is little to no evidence , holding chemotherapy to the white counting pulse an arbitrary number is safer." Finally, I asked him about the consequences of delaying a cycle. He told me that, "There is published data that delaying a cycle by more than 7 days does worsen the results. There is also data that a lower cisplatin dose intensity, measured in mg/m2/week, does worse. The standard EP dose intensity is 33 mg/m2/wk and we know that 20/mg/m2/week is worse. No one knows whether a 3 day delay is harmful, but it certainly is inconvenient to not get your chemo on time, and there is no evidence that waiting until an artificially determined number of white cells has anything to do with risk of infection. This is a very unscientific area."